IP Library › Granted Patent US 10,376,504
Granted Patent B2
US 10,376,504 · App. 15/745,838 · Granted Aug 13, 2019

Substituted quinolinones as PDE9 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,504
App. No.
15/745,838
Granted
Aug 13, 2019
Kind
B2
Abstract

The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R 5 and R 6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Claims (3)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an inert carrier and a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2018
From: CONVERSO, ANTONELLA; RODZINAK, KEVIN J.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 044683/0914 →